NEWS R E L E A S E

Ocumetics Completes Virtual Site Initiation for First-In-Human Clinical Study of Accommodating Intraocular Lens

For Immediate Release

Calgary, Alberta – June 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the successful completion of a virtual site initiation visit at its clinical partner site in Mexico City. This critical milestone confirms that the investigative site is fully prepared to conduct the upcoming first-in-human (FIH) clinical study of its revolutionary accommodating intraocular lens (the “Ocumetics Lens”), in accordance with international standards.

Dean Burns, CEO of Ocumetics commented on the significance of the site inspection: “Conducting the clinical partner site initiation is a major step forward in bringing the Ocumetics Lens to clinical reality. The site initiation occurred remotely and will be finalized when our team visits the site. Successful completion of this critical process confirms clinical readiness to commence the study and to perform surgeries on our first patients. We couldn’t be more excited to proceed to validate the clinical environment for what will be a landmark moment in Ocumetics’ history.”

The site initiation assesses the site’s infrastructure, clinical workflows, equipment compatibility, and staff training. This thorough evaluation ensures that all elements are in place to support a safe, effective, and compliant clinical trial environment.

Following a successful site initiation, the clinical site is now preparing for final activation, enabling patient screening and selection to begin in preparation or FIH surgeries.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns	Roger Jewett
President and Chief Executive Officer	Chief Financial Officer
(817) 874-7564	roger.jewett@ocumetics.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.